Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT04663321. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT04663321
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
This study evaluates the safety and effectiveness of MK-1942 for people with depression.
Medication studyAges 18–65United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of MK-1942 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Birmingham, United States · Little Rock, United States and 41 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Medication and placebo comparator listed across study groups
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 20, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 99
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04663321
- Official title
Show the full official title
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression
Recruitment & locations
TerminatedBirmingham · Little Rock · Bellflower
40 more locations
- Colton
- Garden Grove
- Santa Ana
- Hartford
- Fort Myers
- Hallandale
- Jacksonville
- Lauderhill
- Miami
- Naples
- Orlando
- Tampa
- Winter Park
- Atlanta
- Decatur
- Marietta
- Savannah
- Chicago
- Gaithersburg
- Boston
- Ann Arbor
- Las Vegas
- Berlin
- Princeton
- Albuquerque
- New York
- Staten Island
- Charlotte
- Hickory
- North Canton
- Oklahoma City
- Media
- Philadelphia
- Plymouth Meeting
- Houston
- Plano
- Draper
- Woodstock
- Bellevue
- Everett
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of MK-1942 for people with depression.
Who is behind this study?
The study sponsor is Merck Sharp & Dohme LLC.
Does this study involve medication?
Yes. The study involves medication, including MK-1942 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT02389712
16-week Comparative Effectiveness study of Lamotrigine vs. Fluoxetine for Depression in bipolarity
United States
TerminatedNCT05169710
Investigational Drug for depression
United States, Canada, Bulgaria, + 3 others
TerminatedNCT05227209
Safety study of investigational Drug in depression
United States, Bulgaria, Japan